Replimune Group - REPL Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $16.67
  • Forecasted Upside: 60.88%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$10.36
▲ +0.44 (4.44%)

This chart shows the closing price for REPL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Replimune Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for REPL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for REPL

Analyst Price Target is $16.67
▲ +60.88% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Replimune Group in the last 3 months. The average price target is $16.67, with a high forecast of $17.00 and a low forecast of $16.00. The average price target represents a 60.88% upside from the last price of $10.36.

This chart shows the closing price for REPL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Replimune Group. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/20/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/19/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/17/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/15/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/14/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/13/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/13/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/7/2024BarclaysBoost TargetOverweight ➝ Overweight$13.00 ➝ $17.00Low
6/7/2024HC WainwrightBoost TargetBuy ➝ Buy$12.00 ➝ $17.00Low
6/6/2024WedbushReiterated RatingOutperform$16.00Low
12/6/2023BarclaysLower TargetOverweight ➝ Overweight$50.00 ➝ $13.00Low
11/13/2023HC WainwrightLower TargetBuy ➝ Buy$50.00 ➝ $48.00Low
11/8/2023WedbushReiterated RatingOutperform ➝ Outperform$52.00Low
8/7/2023HC WainwrightLower TargetBuy ➝ Buy$51.00 ➝ $50.00Low
8/1/2023HC WainwrightReiterated RatingBuy ➝ Buy$51.00Low
6/5/2023HC WainwrightBoost Target$50.00 ➝ $51.00Low
4/17/2023Piper SandlerReiterated RatingOverweight$44.00Low
2/10/2023HC WainwrightBoost TargetBuy$48.00 ➝ $50.00Low
1/5/2023EF Hutton Acquisition Co. IInitiated CoverageBuy$60.00Low
12/14/2022Piper SandlerBoost Target$43.00 ➝ $58.00Low
12/12/2022BMO Capital MarketsBoost TargetOutperform$40.00 ➝ $70.00Low
12/7/2022SVB LeerinkBoost TargetOutperform$30.00 ➝ $34.00Low
11/4/2022HC WainwrightLower TargetBuy$60.00 ➝ $48.00Low
10/14/2022BMO Capital MarketsBoost TargetOutperform$30.00 ➝ $40.00Low
10/3/2022SVB LeerinkLower TargetOutperform$37.00 ➝ $30.00Low
8/22/2022Piper SandlerLower Target$43.00Low
8/16/2022Piper SandlerLower TargetOverweight$44.00 ➝ $43.00Low
8/5/2022SVB LeerinkLower TargetOutperform$48.00 ➝ $37.00Low
5/24/2022HC WainwrightReiterated RatingBuy$60.00High
5/24/2022WedbushLower TargetOutperform$59.00 ➝ $52.00Low
5/20/2022SVB LeerinkLower TargetOutperform$49.00 ➝ $48.00High
5/19/2022Piper SandlerLower Target$52.00 ➝ $44.00Medium
4/4/2022JPMorgan Chase & Co.Lower TargetOverweight$47.00 ➝ $39.00High
3/18/2022BMO Capital MarketsLower TargetOutperform$51.00 ➝ $30.00High
1/11/2022HC WainwrightReiterated RatingBuy$60.00Low
11/19/2021Piper SandlerInitiated CoverageOverweight$52.00High
11/15/2021HC WainwrightReiterated RatingBuy$59.00Medium
10/15/2021BTIG ResearchInitiated CoverageBuy$60.00High
8/23/2021SVB LeerinkLower TargetOutperform$55.00 ➝ $49.00High
8/9/2021HC WainwrightReiterated RatingBuy$60.00Low
8/9/2021SVB LeerinkLower TargetOutperform$56.00 ➝ $55.00Medium
2/5/2021HC WainwrightBoost TargetBuy$58.00 ➝ $60.00Medium
2/4/2021SVB LeerinkLower TargetOutperform$57.00 ➝ $56.00Medium
11/17/2020BTIG ResearchInitiated CoverageBuy$60.00High
11/10/2020HC WainwrightBoost TargetBuy$54.00 ➝ $58.00Low
11/6/2020BMO Capital MarketsBoost TargetOutperform$51.00 ➝ $57.00High
11/2/2020Jefferies Financial GroupInitiated CoverageBuy$67.00High
10/15/2020BMO Capital MarketsBoost TargetPositive ➝ Outperform$40.00 ➝ $51.00High
10/15/2020BarclaysBoost TargetOverweight$29.00 ➝ $50.00High
10/15/2020HC WainwrightUpgradeNeutral ➝ Buy$25.00 ➝ $54.00High
10/15/2020SVB LeerinkBoost TargetOutperform$27.00 ➝ $44.00High
10/14/2020Roth CapitalBoost TargetBuy$30.00 ➝ $50.00High
10/14/2020Chardan CapitalBoost TargetBuy$30.00 ➝ $48.00High
8/7/2020Chardan CapitalReiterated RatingBuy$30.00High
8/7/2020SVB LeerinkBoost TargetOutperform$25.00 ➝ $27.00Low
7/1/2020HC WainwrightReiterated RatingBuy ➝ Neutral$25.00High
6/4/2020BMO Capital MarketsBoost TargetOutperform$31.00 ➝ $40.00High
6/4/2020HC WainwrightReiterated RatingBuy$24.00 ➝ $25.00High
6/4/2020BarclaysBoost TargetOverweight$21.00 ➝ $25.00High
6/4/2020Chardan CapitalReiterated RatingBuy$29.00High
6/3/2020WedbushReiterated RatingOutperformMedium
5/4/2020BarclaysInitiated CoverageOverweight$21.00High
2/13/2020Chardan CapitalReiterated RatingBuy$28.00Low
1/21/2020HC WainwrightReiterated RatingBuy$26.00 ➝ $24.00High
11/20/2019WedbushLower TargetOutperform$30.00 ➝ $12.50Medium
11/11/2019Roth CapitalBoost TargetBuy$20.00 ➝ $30.00Low
10/24/2019Chardan CapitalReiterated RatingBuy$28.00Low
10/15/2019Chardan CapitalSet TargetBuy$28.00High
9/30/2019HC WainwrightReiterated RatingBuy$26.00Low
9/4/2019Roth CapitalInitiated CoverageBuy$20.00High
8/15/2019Chardan CapitalReiterated RatingBuy$28.00Medium
7/23/2019Chardan CapitalInitiated CoverageBuy ➝ Buy$28.00Low
(Data available from 7/14/2019 forward)

News Sentiment Rating

0.86 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
12/17/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/16/2024
  • 4 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
2/15/2024
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/16/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/15/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/15/2024
  • 13 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/14/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/14/2024

Current Sentiment

  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Replimune Group logo
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Read More

Today's Range

Now: $10.36
Low: $9.87
High: $10.57

50 Day Range

MA: $7.37
Low: $5.01
High: $10.36

52 Week Range

Now: $10.36
Low: $4.92
High: $22.21

Volume

721,168 shs

Average Volume

1,381,353 shs

Market Capitalization

$636.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25

Frequently Asked Questions

What sell-side analysts currently cover shares of Replimune Group?

The following Wall Street research analysts have issued research reports on Replimune Group in the last twelve months: Barclays PLC, HC Wainwright, and Wedbush.
View the latest analyst ratings for REPL.

What is the current price target for Replimune Group?

3 Wall Street analysts have set twelve-month price targets for Replimune Group in the last year. Their average twelve-month price target is $16.67, suggesting a possible upside of 60.9%. Barclays PLC has the highest price target set, predicting REPL will reach $17.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $16.00 for Replimune Group in the next year.
View the latest price targets for REPL.

What is the current consensus analyst rating for Replimune Group?

Replimune Group currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe REPL will outperform the market and that investors should add to their positions of Replimune Group.
View the latest ratings for REPL.

What other companies compete with Replimune Group?

How do I contact Replimune Group's investor relations team?

Replimune Group's physical mailing address is 500 Unicorn Park, WOBURN MA, 01801. The company's listed phone number is (781) 222-9600 and its investor relations email address is [email protected]. The official website for Replimune Group is www.replimune.com. Learn More about contacing Replimune Group investor relations.